Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project

BioBank Japan Cooperative Hospital Group

研究成果: Article

3 引用 (Scopus)

抄録

Background: Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project. Methods: Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated. Results: Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing. Conclusions: We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput "omics" technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.

元の言語English
ページ(範囲)S65-S70
ジャーナルJournal of epidemiology
27
発行部数3
DOI
出版物ステータスPublished - 01-01-2017

Fingerprint

Prostatic Neoplasms
Japan
Survival Rate
Prostate-Specific Antigen
Cause of Death
Adenocarcinoma
Body Mass Index
Cohort Studies
Exercise
Technology
Neoplasms

All Science Journal Classification (ASJC) codes

  • Epidemiology

これを引用

BioBank Japan Cooperative Hospital Group. / Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project. :: Journal of epidemiology. 2017 ; 巻 27, 番号 3. pp. S65-S70.
@article{e95528a4f05244e48fc4a8d11f0d67f4,
title = "Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project",
abstract = "Background: Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project. Methods: Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated. Results: Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7{\%}, 28.0{\%}, 66.6{\%}, 58.1{\%}, 67.6{\%}, and 6.5{\%}, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4{\%}, 7.3{\%}, and 4.4{\%}, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3{\%} and 100.5{\%}, respectively, although we were unable to consider management strategies due to a plenty of data missing. Conclusions: We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput {"}omics{"} technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.",
author = "{BioBank Japan Cooperative Hospital Group} and Shigekazu Ukawa and Koshi Nakamura and Emiko Okada and Makoto Hirata and Akiko Nagai and Zentaro Yamagata and Kaori Muto and Koichi Matsuda and Toshiharu Ninomiya and Yutaka Kiyohara and Yoichiro Kamatani and Michiaki Kubo and Yusuke Nakamura and Akiko Tamakoshi and Ichiro Miura and Katsuhiko Takatama and Yoshiyuki Nabeshima and Kazuo Misumi and Shiro Minami and Yukihiro Kondo and Go Kimura and Shigeo Horie and Shinichi Ohba and Shigaku Ikeda and Satoshi Asai and Mitsuhiko Moriyama and Yasuo Takahashi and Tomoaki Fujioka and Wataru Obara and Seijiro Mori and Hideki Ito and Satoshi Nagayama and Yoshio Miki and Akihide Masumoto and Akira Yamada and Yasuko Nishizawa and Ken Kodama and Keisei Okamoto and Susumu Kageyama and Yukihiro Koretsune and Yuko Nishigaki and Tsutomu Yoshida",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.je.2016.12.008",
language = "English",
volume = "27",
pages = "S65--S70",
journal = "Journal of Epidemiology",
issn = "0917-5040",
publisher = "Japan Epidemiology Association",
number = "3",

}

Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project. / BioBank Japan Cooperative Hospital Group.

:: Journal of epidemiology, 巻 27, 番号 3, 01.01.2017, p. S65-S70.

研究成果: Article

TY - JOUR

T1 - Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project

AU - BioBank Japan Cooperative Hospital Group

AU - Ukawa, Shigekazu

AU - Nakamura, Koshi

AU - Okada, Emiko

AU - Hirata, Makoto

AU - Nagai, Akiko

AU - Yamagata, Zentaro

AU - Muto, Kaori

AU - Matsuda, Koichi

AU - Ninomiya, Toshiharu

AU - Kiyohara, Yutaka

AU - Kamatani, Yoichiro

AU - Kubo, Michiaki

AU - Nakamura, Yusuke

AU - Tamakoshi, Akiko

AU - Miura, Ichiro

AU - Takatama, Katsuhiko

AU - Nabeshima, Yoshiyuki

AU - Misumi, Kazuo

AU - Minami, Shiro

AU - Kondo, Yukihiro

AU - Kimura, Go

AU - Horie, Shigeo

AU - Ohba, Shinichi

AU - Ikeda, Shigaku

AU - Asai, Satoshi

AU - Moriyama, Mitsuhiko

AU - Takahashi, Yasuo

AU - Fujioka, Tomoaki

AU - Obara, Wataru

AU - Mori, Seijiro

AU - Ito, Hideki

AU - Nagayama, Satoshi

AU - Miki, Yoshio

AU - Masumoto, Akihide

AU - Yamada, Akira

AU - Nishizawa, Yasuko

AU - Kodama, Ken

AU - Okamoto, Keisei

AU - Kageyama, Susumu

AU - Koretsune, Yukihiro

AU - Nishigaki, Yuko

AU - Yoshida, Tsutomu

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project. Methods: Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated. Results: Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing. Conclusions: We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput "omics" technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.

AB - Background: Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project. Methods: Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated. Results: Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing. Conclusions: We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput "omics" technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85016394019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016394019&partnerID=8YFLogxK

U2 - 10.1016/j.je.2016.12.008

DO - 10.1016/j.je.2016.12.008

M3 - Article

C2 - 28215481

AN - SCOPUS:85016394019

VL - 27

SP - S65-S70

JO - Journal of Epidemiology

JF - Journal of Epidemiology

SN - 0917-5040

IS - 3

ER -